The invention relates a pharmaceutical composition comprising a combination of: (i) the AT 1-antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's, glaucoma and stroke, comprising administering a therapeutically effective amount of the pharmaceutical composition to a mammal in need thereof. Inventor(s): Ksander Gary Michael & Webb Randy Lee Methods of treatment and pharmaceutical composition.Patent use: TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION Patent and Trademark Office at any time during a drug's development and may include a wide range of claims. Ask your health care provider for advice if you are unsure about the online purchase of any medication. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. These medications may be counterfeit and potentially unsafe. Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Entresto. There is currently no therapeutically equivalent version of Entresto available in the United States. Has a generic version of Entresto been approved? Entresto is a brand name of sacubitril/valsartan, approved by the FDA in the following formulation(s): ENTRESTO (sacubitril valsartan - tablet oral)
0 kommentar(er)
